{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:17:07Z","timestamp":1786979827477,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2016,6,29]],"date-time":"2016-06-29T00:00:00Z","timestamp":1467158400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s00228-016-2087-0","type":"journal-article","created":{"date-parts":[[2016,6,28]],"date-time":"2016-06-28T22:37:58Z","timestamp":1467153478000},"page":"1099-1104","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Impact of age, gender and CYP2C9\/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid\u2014a large-scale study based on naturalistic therapeutic drug monitoring data"],"prefix":"10.1007","volume":"72","author":[{"given":"R. L.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Haslemo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Refsum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Molden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,29]]},"reference":[{"key":"2087_CR1","first-page":"707","volume":"124","author":"PA Lambert","year":"1966","unstructured":"Lambert PA, Carraz G, Borselli S, Carbel S (1966) Neuropsychotropic action of a new anti-epileptic agent: depamide. Ann Med Psychol (Paris) 124:707\u2013710","journal-title":"Ann Med Psychol (Paris)"},{"key":"2087_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003196.pub2","volume":"10","author":"A Cipriani","year":"2013","unstructured":"Cipriani A, Reid K, Young AH, Macritchie K, Geddes J (2013) Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev 10, CD003196. doi: 10.1002\/14651858.CD003196.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"2087_CR3","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/(SICI)1099-081X(199907)20:5<233::AID-BDD179>3.0.CO;2-5","volume":"20","author":"B Blanco-Serrano","year":"1999","unstructured":"Blanco-Serrano B, Otero MJ, Santos-Buelga D, Garcia-Sanchez MJ, Serrano J, Dominguez-Gil A (1999) Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data. Biopharm Drug Dispos 20:233\u2013240","journal-title":"Biopharm Drug Dispos"},{"key":"2087_CR4","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10545-008-0841-x","volume":"31","author":"MF Silva","year":"2008","unstructured":"Silva MF, Aires CC, Luis PB, Ruiter JP, IJlst L, Duran M, Wanders RJ, Tavares de Almeida I (2008) Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. J Inherit Metab Dis 31:205\u2013216. doi: 10.1007\/s10545-008-0841-x","journal-title":"J Inherit Metab Dis"},{"key":"2087_CR5","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1124\/dmd.108.022426","volume":"37","author":"UA Argikar","year":"2009","unstructured":"Argikar UA, Remmel RP (2009) Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos 37:229\u2013236. doi: 10.1124\/dmd.108.022426","journal-title":"Drug Metab Dispos"},{"key":"2087_CR6","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/FPC.0b013e32835ea0b2","volume":"23","author":"Y Ghodke-Puranik","year":"2013","unstructured":"Ghodke-Puranik Y, Thorn CF, Lamba JK, Leeder JS, Song W, Birnbaum AK, Altman RB, Klein TE (2013) Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics 23:236\u2013241. doi: 10.1097\/FPC.0b013e32835ea0b2","journal-title":"Pharmacogenet Genomics"},{"key":"2087_CR7","doi-asserted-by":"crossref","first-page":"13733","DOI":"10.1016\/S0021-9258(18)68302-4","volume":"263","author":"AE Rettie","year":"1988","unstructured":"Rettie AE, Boberg M, Rettenmeier AW, Baillie TA (1988) Cytochrome P-450-catalyzed desaturation of valproic acid in vitro. Species differences, induction effects, and mechanistic studies. J Biol Chem 263:13733\u201313738","journal-title":"J Biol Chem"},{"key":"2087_CR8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/toxsci\/kfl096","volume":"94","author":"TK Kiang","year":"2006","unstructured":"Kiang TK, Ho PC, Anari MR, Tong V, Abbott FS, Chang TK (2006) Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1\/*1 genotype. Toxicol Sci 94:261\u2013271. doi: 10.1093\/toxsci\/kfl096","journal-title":"Toxicol Sci"},{"key":"2087_CR9","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s00228-012-1277-7","volume":"68","author":"XM Chu","year":"2012","unstructured":"Chu XM, Zhang LF, Wang GJ, Zhang SN, Zhou JH, Hao HP (2012) Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients. Eur J Clin Pharmacol 68:1395\u20131401. doi: 10.1007\/s00228-012-1277-7","journal-title":"Eur J Clin Pharmacol"},{"key":"2087_CR10","unstructured":"FDA approved product label: valproic acid (2016). Accessed 6 june 2016"},{"key":"2087_CR11","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1365-2125.1984.tb02401.x","volume":"17","author":"E Perucca","year":"1984","unstructured":"Perucca E, Grimaldi R, Gatti G, Pirracchio S, Crema F, Frigo GM (1984) Pharmacokinetics of valproic acid in the elderly. Br J Clin Pharmacol 17:665\u2013669","journal-title":"Br J Clin Pharmacol"},{"key":"2087_CR12","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/clpt.1985.116","volume":"37","author":"LA Bauer","year":"1985","unstructured":"Bauer LA, Davis R, Wilensky A, Raisys V, Levy RH (1985) Valproic acid clearance: unbound fraction and diurnal variation in young and elderly adults. Clin Pharmacol Ther 37:697\u2013700","journal-title":"Clin Pharmacol Ther"},{"key":"2087_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.eplepsyres.2006.04.002","volume":"70","author":"C Fattore","year":"2006","unstructured":"Fattore C, Messina S, Battino D, Croci D, Mamoli D, Perucca E (2006) The influence of old age and enzyme inducing comedication on the pharmacokinetics of valproic acid at steady-state: a case-matched evaluation based on therapeutic drug monitoring data. Epilepsy Res 70:153\u2013160. doi: 10.1016\/j.eplepsyres.2006.04.002","journal-title":"Epilepsy Res"},{"key":"2087_CR14","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10928-013-9323-3","volume":"40","author":"M Ibarra","year":"2013","unstructured":"Ibarra M, Vazquez M, Fagiolino P, Derendorf H (2013) Sex related differences on valproic acid pharmacokinetics after oral single dose. J Pharmacokinet Pharmacodyn 40:479\u2013486. doi: 10.1007\/s10928-013-9323-3","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2087_CR15","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1097\/FTD.0b013e31811f3296","volume":"29","author":"AK Birnbaum","year":"2007","unstructured":"Birnbaum AK, Ahn JE, Brundage RC, Hardie NA, Conway JM, Leppik IE (2007) Population pharmacokinetics of valproic acid concentrations in elderly nursing home residents. Ther Drug Monit 29:571\u2013575. doi: 10.1097\/FTD.0b013e31811f3296","journal-title":"Ther Drug Monit"},{"key":"2087_CR16","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/01.ftd.0000189899.23931.76","volume":"28","author":"I Rudberg","year":"2006","unstructured":"Rudberg I, Hendset M, Uthus LH, Molden E, Refsum H (2006) Heterozygous mutation in CYP2C19 significantly increases the concentration\/dose ratio of racemic citalopram and escitalopram (S-citalopram). Ther Drug Monit 28:102\u2013105","journal-title":"Ther Drug Monit"},{"key":"2087_CR17","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00228-010-0813-6","volume":"66","author":"E Molden","year":"2010","unstructured":"Molden E, Okkenhaug C, Ekker Solberg E (2010) Increased frequency of CYP2C9 variant alleles and homozygous VKORC1*2B carriers in warfarin-treated patients with excessive INR response. Eur J Clin Pharmacol 66:525\u2013530. doi: 10.1007\/s00228-010-0813-6","journal-title":"Eur J Clin Pharmacol"},{"key":"2087_CR18","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/sj.clpt.6100291","volume":"83","author":"I Rudberg","year":"2008","unstructured":"Rudberg I, Mohebi B, Hermann M, Refsum H, Molden E (2008) Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther 83:322\u2013327. doi: 10.1038\/sj.clpt.6100291","journal-title":"Clin Pharmacol Ther"},{"key":"2087_CR19","unstructured":"World Health Organization: definition of an older or elderly person (2016). Accessed 7 june 2016"},{"key":"2087_CR20","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s00228-009-0712-x","volume":"65","author":"D Jiang","year":"2009","unstructured":"Jiang D, Bai X, Zhang Q, Lu W, Wang Y, Li L, Muller M (2009) Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients: nonlinear mixed-effect modeling. Eur J Clin Pharmacol 65:1187\u20131193. doi: 10.1007\/s00228-009-0712-x","journal-title":"Eur J Clin Pharmacol"},{"key":"2087_CR21","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.clineuro.2010.01.002","volume":"112","author":"L Tan","year":"2010","unstructured":"Tan L, Yu JT, Sun YP, Ou JR, Song JH, Yu Y (2010) The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients. Clin Neurol Neurosurg 112:320\u2013323. doi: 10.1016\/j.clineuro.2010.01.002","journal-title":"Clin Neurol Neurosurg"},{"key":"2087_CR22","doi-asserted-by":"crossref","first-page":"536","DOI":"10.2133\/dmpk.DMPK-11-NT-144","volume":"27","author":"Y Guo","year":"2012","unstructured":"Guo Y, Hu C, He X, Qiu F, Zhao L (2012) Effects of UGT1A6, UGT2B7, and CYP2C9 genotypes on plasma concentrations of valproic acid in Chinese children with epilepsy. Drug Metab Pharmacokinet 27:536\u2013542","journal-title":"Drug Metab Pharmacokinet"},{"key":"2087_CR23","doi-asserted-by":"publisher","first-page":"452","DOI":"10.3109\/15376516.2010.497977","volume":"20","author":"N Amini-Shirazi","year":"2010","unstructured":"Amini-Shirazi N, Ghahremani MH, Ahmadkhaniha R, Mandegary A, Dadgar A, Abdollahi M, Shadnia S, Pakdaman H, Kebriaeezadeh A (2010) Influence of CYP2C9 polymorphism on metabolism of valproate and its hepatotoxin metabolite in Iranian patients. Toxicol Mech Methods 20:452\u2013457. doi: 10.3109\/15376516.2010.497977","journal-title":"Toxicol Mech Methods"},{"key":"2087_CR24","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/sj.clpt.6100324","volume":"83","author":"JY Chung","year":"2008","unstructured":"Chung JY, Cho JY, Yu KS, Kim JR, Lim KS, Sohn DR, Shin SG, Jang IJ (2008) Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther 83:595\u2013600. doi: 10.1038\/sj.clpt.6100324","journal-title":"Clin Pharmacol Ther"},{"key":"2087_CR25","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1124\/jpet.104.081968","volume":"313","author":"S Krishnaswamy","year":"2005","unstructured":"Krishnaswamy S, Hao Q, Al-Rohaimi A, Hesse LM, von Moltke LL, Greenblatt DJ, Court MH (2005) UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J Pharmacol Exp Ther 313:1340\u20131346. doi: 10.1124\/jpet.104.081968","journal-title":"J Pharmacol Exp Ther"},{"key":"2087_CR26","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1097\/FTD.0000000000000012","volume":"36","author":"K Inoue","year":"2014","unstructured":"Inoue K, Suzuki E, Yazawa R, Yamamoto Y, Takahashi T, Takahashi Y, Imai K, Koyama S, Inoue Y, Tsuji D, Hayashi H, Itoh K (2014) Influence of uridine diphosphate glucuronosyltransferase 2B7 -161C\u2009>\u2009T polymorphism on the concentration of valproic acid in pediatric epilepsy patients. Ther Drug Monit 36:406\u2013409. doi: 10.1097\/FTD.0000000000000012","journal-title":"Ther Drug Monit"},{"key":"2087_CR27","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00008571-199408000-00005","volume":"4","author":"KW Bock","year":"1994","unstructured":"Bock KW, Schrenk D, Forster A, Griese EU, Morike K, Brockmeier D, Eichelbaum M (1994) The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics 4:209\u2013218","journal-title":"Pharmacogenetics"},{"key":"2087_CR28","first-page":"998","volume":"299","author":"MH Court","year":"2001","unstructured":"Court MH, Duan SX, von Moltke LL, Greenblatt DJ, Patten CJ, Miners JO, Mackenzie PI (2001) Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J Pharmacol Exp Ther 299:998\u20131006","journal-title":"J Pharmacol Exp Ther"},{"key":"2087_CR29","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1097\/01.mjt.0000183719.84390.4d","volume":"14","author":"ES ElDesoky","year":"2007","unstructured":"ElDesoky ES (2007) Pharmacokinetic-pharmacodynamic crisis in the elderly. Am J Ther 14:488\u2013498. doi: 10.1097\/01.mjt.0000183719.84390.4d","journal-title":"Am J Ther"},{"key":"2087_CR30","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2174\/138920011796504473","volume":"12","author":"G Trifiro","year":"2011","unstructured":"Trifiro G, Spina E (2011) Age-related changes in pharmacodynamics: focus on drugs acting on central nervous and cardiovascular systems. Curr Drug Metab 12:611\u2013620","journal-title":"Curr Drug Metab"},{"key":"2087_CR31","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2174\/092986710790416326","volume":"17","author":"A Corsonello","year":"2010","unstructured":"Corsonello A, Pedone C, Incalzi RA (2010) Age-related pharmacokinetic and pharmacodynamic changes and related risk of adverse drug reactions. Curr Med Chem 17:571\u2013584","journal-title":"Curr Med Chem"},{"key":"2087_CR32","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1080\/00498250701744633","volume":"38","author":"H Jeong","year":"2008","unstructured":"Jeong H, Choi S, Song JW, Chen H, Fischer JH (2008) Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination. Xenobiotica 38:62\u201375. doi: 10.1080\/00498250701744633","journal-title":"Xenobiotica"},{"key":"2087_CR33","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1124\/dmd.109.026609","volume":"37","author":"H Chen","year":"2009","unstructured":"Chen H, Yang K, Choi S, Fischer JH, Jeong H (2009) Up-regulation of UDP-glucuronosyltransferase (UGT) 1A4 by 17beta-estradiol: a potential mechanism of increased lamotrigine elimination in pregnancy. Drug Metab Dispos 37:1841\u20131847. doi: 10.1124\/dmd.109.026609","journal-title":"Drug Metab Dispos"},{"key":"2087_CR34","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2147\/TCRM.S1458","volume":"4","author":"J Jin","year":"2008","unstructured":"Jin J, Sklar GE, Min Sen Oh V, Chuen Li S (2008) Factors affecting therapeutic compliance: a review from the patient\u2019s perspective. Ther Clin Risk Manag 4:269\u2013286","journal-title":"Ther Clin Risk Manag"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-016-2087-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-016-2087-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-016-2087-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T05:20:39Z","timestamp":1656739239000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-016-2087-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,29]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["2087"],"URL":"https:\/\/doi.org\/10.1007\/s00228-016-2087-0","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,29]]}}}